The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Updated Diagnostic Criteria and Staging System for Multiple Myeloma
Abstract
There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The median survival of the disease has doubled as a result of several new active drugs. These advances have necessitated a revision of the disease definition and staging of MM. Until recently, MM was defined by the presence of end-organ damage, specifically hypercalcemia, renal failure, anemia, and bone lesions (CRAB features) that can be attributed to the clonal process. In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM to add three specific biomarkers that can be used to diagnose the disease in patients who did not have CRAB features: clonal bone marrow plasma cells greater than or equal to 60%, serum free light chain (FLC) ratio greater than or equal to 100 provided involved FLC level is 100 mg/L or higher, or more than one focal lesion on MRI. In addition, the definition was revised to allow CT and PET-CT to diagnose MM bone disease. These changes enable early diagnosis and allow the initiation of effective therapy to prevent the development of end-organ damage for patients who are at the highest risk. A new staging system has been developed that incorporates high-risk cytogenetic abnormalities in addition to standard laboratory markers of prognosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 5 year survival rates among the patients with Stage I, II, and III RISS were 82%, 62%, and 40%, respectively [20].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
In the citing paper
“In an international clinical trial with 3060 participants, for those with stage I disease, overall survival (OS) and progression-free survival (PFS) at five years was 82% and 55%, respectively. Median PFS was 66 months, and OS was not reached.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
In the citing paper
“For Stage III disease, these values were 40%, 24%—29 months and 43 months, respectively.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
In the citing paper
“For Stage II disease, these values were 62% and 36%, 42 months and 83 months, respectively.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
In the citing paper
“Both the ISS and DSS systems assess the tumor burden, but neither ISS nor DSS takes into consideration the biology of the disease, which determines the overall survival [20,21,22].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
In the citing paper
“The revised ISS adds prognostic information such as lactate dehydrogenase (LDH) levels and chromosomal abnormalities detected via FISH.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [20]
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationA Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationLenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citationKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citationA monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568
Cited by
Sorted by citations
Items 301–348 of 348
Chang, C., Ho, J.-L., Lin, P.-C., Lin, C.-P., Tsai, W.-T., Huang, H.-L., Yu, Y., Chen, W., & Chu, F. (2024) · Medicine · doi:10.1097/md.0000000000038523
Molecular Progression and Multiple-Target Biomarkers in Multiple Myeloma: A Brief Review
Kalantari, T. (2023) · Cancer Research and Cellular Therapeutics · doi:10.31579/2640-1053/170
Update in the imaging study of multiple myeloma
Daniela Barahona, Z. (2024) · Austral Journal of Imaging (English Edition) · doi:10.24875/aji.m24000029
Benefits of serum protein electrophoresis as part of hematopoietic stem cell donor clearance
Kilinc, L., Schleipen, B., Ende, K., Buk, D. M., Schmidt, A. H., Auer, I., & Mengling, T. (2024) · eJHaem · doi:10.1002/jha2.997
Warning values of serum total kappa/lambda ratio for M-proteinemia
Lu, J., Zhu, Y., Huang, H., Yang, Q., & Qi, S. (2024) · BMC Immunology · doi:10.1186/s12865-024-00664-6
Kottahachchi, D. U., Hewapathirana, T. D., Perera, T. C., & Suresh, S. (2024) · شهباز. · doi:10.61186/mlj.18.2.11
Plasma Cell Myeloma and Related Disorders
Tute, R. M. D., Rawstron, A. C., Owen, R. G., Porwit‐MacDonald, A., & Béné, M. C. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009419086.009
Szita, V. R. (2025) · Hematológia–Transzfuziológia · doi:10.1556/2068.2025.00202
Whole-body MRI for a patient with progressive multiple myeloma
Henning, J., Nishihori, T., Freeman, C. L. L., Lazarides, A. L., Song, J., Kuruvilla, D., Feuerlein, S., & Costello, J. R. (2025) · BJR|case reports · doi:10.1093/bjrcr/uaaf028
Musbau, T., & Al-Bubseeree, B. (2025) · Cureus · doi:10.7759/cureus.83730
Solitary Extramedullary Plasmacytoma of Larynx - A Case Report
Rana, S., Surampuri, S., Chaudhoory, A. R., Pannu, J., Chauhan, S., Jain, P., Anand, A. K., & Raina, V. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02036-6
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1197
Li, F., Jiang, B., Fu, Y., Yu, Q., Duan, G., Yan, J., Jiang, Q., Sun, H., Xiao, Y., Chen, Q., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1486495
Reshmy, G. S., Krishnan, S., Unni, M., Gutjahr, G., Mathew, M., Soman, A., & Sidharthan, N. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02130-8
Novellis, D. D., Palmieri, S., Rocco, S., Derudas, D., Pepa, R. D., Roccotelli, D., Esposito, D., Masucci, C., Gigliotta, E., Barone, M. L., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06572-y
del Río, M. T. C., Enciso, B. S., & Gómez, J. L. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102574
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1228
Perumal, H. A., Nagarajan, S., Ullattil, P. K., Unnikrishnan, M. K., Nair, A. R., & Dutta, D. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04086-x
Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma
Shifrin, Y., & Mai, S. (2025) · Cells · doi:10.3390/cells14231890
Liu, M., Jian, Y., Zhou, H., Jia, J., Li, J., Geng, C., Yang, G., Huang, W., Cen, X., Chen, W., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.72054
Sporadic Late-onset Nemaline Myopathy Associated with Multiple Myeloma
Furukawa, Y., Hokkoku, K., Furukawa, Y., Hagiwara, Y., Kubota, A., Shimizu, J., Shirasaki, R., & Kobayashi, S. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6344-25
Byun, J. M., Min, C.-K., Kim, K., Bang, S.-M., Lee, J.-J., Kim, J. S., Yoon, S.-S., & Koh, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21385900
Choi, J., Khoo, S., & Wu, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-53888-9_36-1
Wu, L., Li, Y., & Li, H. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1578132
Singh, M., Sanjeev, Y., Pandey, A., Rahman, K., Vijayaran, M., Kapoor, P., Roy, S. S., Gupta, R., Chandra, D., Kumar, K., et al. (2026) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.70058
Chiu, L., Wang, M.-C., Ma, M., Liu, H.-L., Liao, B.-H., & Kuo, C.-Y. (2026) · Research Square · doi:10.21203/rs.3.rs-8580991/v1
Mielomul multiplu: progrese recente în diagnostic și tratament (Review integrativ)
BURUIANA, G., Chislaru, L., Schiopu, V., & Buruiana, S. (2026) · Akademos · doi:10.52673/18570461.25.4-79.05
Singh, S., Roshan, R., Jain, K., Nazir, I., Chhabra, A., Rasool, J., & Bansal, E. (2026) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-026-02340-8
Michetti, L., Antelmi, E., Ravasio, R., & Ghirardi, A. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0183
Chen, Y., Gao, S., Zhao, X., Hu, W., & Bao, L. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105427
Caillot, M. (2022) · theses.fr (ABES) · doi:10.70675/69fdc951z6d60z453bzbc0bz632f2f850876
Iannelli, S., Scarcella, M., Cusano, A., Feleppa, F., Pancione, Y., Pavone, L. M., & Cocchiaro, P. (2026) · Clinics and Practice · doi:10.3390/clinpract16040081
Challenges in Predictive Modeling in Multiple Myeloma: A Narrative Approach
Irfan, S., Ali, R. N., Ahmed, N., & Hassan, B. (2026) · Smart innovation, systems and technologies · doi:10.1007/978-3-032-20121-8_17
Raja, S., Huang, H. L., Leung, C., & Gnanasegaran, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-00821-3_23
Machine Learning in Haematological Malignancies: From Early Detection to Precision Therapy
Onuoha, E. C., Hallie, E. F., & Davies-Nwa, O. (2026) · Journal of Artificial Intelligence · doi:10.3923/jai.2026.1.10
Yanamandra, U., Ramachandran, R., Sakhuja, V., Nair, R. K., Jha, V., Kumar, S. K., Leung, N., & Malhotra, P. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.006
Patel, S. K., Moghareh-Dehkordy, S., & White, C. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-273727
Adaş, M., Çörekci, A. M., DEMİRKALE, İ., Berber, T., Uysal, E., AKDEMİR, E., BARIŞ, F., & Yıldırım, B. A. (2026) · Research Square · doi:10.21203/rs.3.rs-9628103/v1
Complementary Role of Whole-Body MRI and CT in Hematologic Malignancies and Bone Marrow Disorders
Ghotbi, E., Frick, M. J., Cook, J., & Baffour, F. I. (2026) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001918
Zhou, M., & Feng, S. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03689-6
Monoclonal Gammopathy of Thrombotic Significance
Ho, M., Zanwar, S., Kumar, S. K., & Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70467
Self-citationStraßl, I., Bindeus, D., Burghofer, J., Erdel, M., Buxhofer‐Ausch, V., Machherndl‐Spandl, S., Saini, O., Wipplinger, D., Kaynak, E., Milanov, R., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1896152
Recurrent Epistaxis as a Rare Presentation of Extramedullary Multiple Myeloma
Kumar, V., Paswan, V., Kumar, P., & Bhargava, R. (2026) · Cureus · doi:10.7759/cureus.114795
EXABS-153-MM: Should We Treat High-Risk SMM With or Without Considering Genetics?
Callander, N. S., & Gahvari, Z. J. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00305-8
Zhang, Q., Xin, Q., & Guo, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1874801
Pham, P. T., Nguyen, H. V., & Vu, M. P. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2026-0267
Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass.
Tamariz-Amador, L., Rodriguez-Otero, P., Manubens, A., Lasa, M., González, C., Paiva, B., & San-Miguel, J. (2026) · Cancer Journal · doi:10.1097/ppo.0000000000000846
Gomes, N. R., do Amaral‐Silva, G. K., SOUZA, L. L. D., de CÁCERES, C. V. B. L., Vargas, P. A., Pontes, H. A. R., Santos‐Silva, A. R., Brandão, T. B., Faria, K. M., Prado-Ribeiro, A. C., et al. (2026) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2026.09.011
Metadata
- Authors
- Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Rajkumar, S. Vincent
- ORCID
- Rajkumar, S. Vincent
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2016-05
- Volume
- 36
- Issue
- 36
- Pages
- e418-e423
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4245689579
- Cited by
- 350
- References
- 33
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 46 · 2023: 50 · 2022: 52 · 2021: 50 · 2020: 32 · 2019: 23 · 2018: 17 · 2017: 14
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, diagnostic criteria, disease staging, serum free light chain ratio, bone lesions, high-risk cytogenetics, prognosis
- MeSH terms
- Positron Emission Tomography Computed Tomography, Bone Marrow Cells, Humans, Magnetic Resonance Imaging, Multiple Myeloma, Neoplasm Staging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
